Insider Trading Alert - UGI, BIIB And CAMP Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 16, 2014, 105 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $63.36 to $15,595,781.10.

Highlighted Stocks Traded by Insiders:

UGI (UGI) - FREE Research Report

Gaudiosi Monica M, who is VP, Gen. Counsel & Secretary at UGI, bought 2,000 shares at $36.45 on Dec. 16, 2014. Following this transaction, the VP, Gen. Counsel & Secretary owned 19,168 shares meaning that the stake was boosted by 11.65% with the 2,000-share transaction.

The shares most recently traded at $36.15, down $0.30, or 0.83% since the insider transaction. Historical insider transactions for UGI go as follows:

  • 4-Week # shares bought: 3,175
  • 4-Week # shares sold: 45,628
  • 12-Week # shares bought: 3,175
  • 12-Week # shares sold: 45,628
  • 24-Week # shares bought: 3,175
  • 24-Week # shares sold: 85,628

The average volume for UGI has been 1.0 million shares per day over the past 30 days. UGI has a market cap of $6.4 billion and is part of the utilities sector and utilities industry. Shares are up 31.48% year-to-date as of the close of trading on Monday.

UGI Corporation, through its subsidiaries, distributes, stores, transports, and markets energy products and related services in the United States and internationally. The stock currently has a dividend yield of 2.36%. The company has a P/E ratio of 19.2. Currently, there is 1 analyst who rates UGI a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on UGI - FREE

TheStreet Quant Ratings rates UGI as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, good cash flow from operations and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full UGI Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Biogen Idec (BIIB) - FREE Research Report

Artavanis-Tsakonas Spyridon, who is SVP, Chief Scientific Officer at Biogen Idec, sold 1,981 shares at $346.50 on Dec. 16, 2014. Following this transaction, the SVP, Chief Scientific Officer owned 352 shares meaning that the stake was reduced by 84.91% with the 1,981-share transaction.

The shares most recently traded at $325.13, down $21.37, or 6.57% since the insider transaction. Historical insider transactions for Biogen Idec go as follows:

  • 4-Week # shares sold: 2,189
  • 12-Week # shares sold: 7,944
  • 24-Week # shares sold: 22,516

The average volume for Biogen Idec has been 1.6 million shares per day over the past 30 days. Biogen Idec has a market cap of $81.4 billion and is part of the health care sector and drugs industry. Shares are up 20.11% year-to-date as of the close of trading on Monday.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of multiple sclerosis (MS), neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. The company has a P/E ratio of 32.6. Currently, there are 12 analysts who rate Biogen Idec a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BIIB - FREE

TheStreet Quant Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, robust revenue growth and largely solid financial position with reasonable debt levels by most measures. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Biogen Idec Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

CalAmp (CAMP) - FREE Research Report

Vitelle Richard K, who is Executive VP & CFO at CalAmp, sold 4,000 shares at $19.04 on Dec. 16, 2014. Following this transaction, the Executive VP & CFO owned 315,613 shares meaning that the stake was reduced by 1.25% with the 4,000-share transaction.

The shares most recently traded at $19.07, up $0.03, or 0.16% since the insider transaction. Historical insider transactions for CalAmp go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 4,000
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 8,000
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 8,000

The average volume for CalAmp has been 693,600 shares per day over the past 30 days. CalAmp has a market cap of $694.6 million and is part of the technology sector and telecommunications industry. Shares are down 31.78% year-to-date as of the close of trading on Monday.

CalAmp Corp. develops and markets wireless communications products and solutions for various applications worldwide. It operates in two segments, Wireless DataCom and Satellite. The company has a P/E ratio of 53.3. Currently, there are 5 analysts who rate CalAmp a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CAMP - FREE

TheStreet Quant Ratings rates CalAmp as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in net income, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full CalAmp Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Component Stocks Rise After Trump Reverses Decision on ZTE

Component Stocks Rise After Trump Reverses Decision on ZTE